Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...
ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results